Table 7.
Effect of the CORE andCQR-300 on plasma and urinary malondialdehyde, 5-HT, and plasma creatinine levels
| Group 1 BMI>30 Placebo (2100 Kcal/day diet) |
Group 2 BMI>30 CORE (no dietary restriction) |
Group 3 BMI>30 CORE (2100 Kcal/day diet) |
Group 4 BMI>30 CQR-300 (2100 Kcal/day diet) |
Group 5 BMI 24–29.9 CORE (no dietary restriction) |
||||||
| Time (weeks) | T = 0 | T = 6 | T = 0 | T = 8 | T = 0 | T = 8 | T = 0 | T = 6 | T = 0 | T = 8 |
| Plasma MDA (μmol/L) | 1.8 ± 0.1 | 1.7 ± 0.1 | 1.8 ± 0.6 | 1.0 ± 0.5* | 1.9 ± 0.9 | 1.1 ± 0.6 *† | 1.6 ± 0.2 | 1.0 ± 0.4* | 1.8 ± 0.3 | 1.2 ± 0.5* |
| Urinary MDA (μmol/day) | 3476.2 ± 211.7 | 3492.2 ± 188.4 | 3864.3 ± 238.4 | 4325.1 ± 167.5* | 4022.1 ± 148.1 | 4485.8 ± 203.3 | 3416.2 ± 110.9 | 3581.5 ± 200.2 | 3593.8 ± 116.5 | 3971.0 ± 104.5 |
| Plasma 5-HT (mgl/dl) | 30.6 ± 1.9 | 35.8 ± 2.1 | 32.5 ± 1.9 | 42.4 ± 3.4* | 38.4 ± 1.5 | 53.4 ± 3.6† | 35.4 ± 1.7 | 54.3 ± 2.9* | 33.1 ± 3.7 | 43.2 ± 2.1* |
| Plasma creatinine (mg/dl) | 25.7 ± 3.8 | 27.3 ± 1.4 | 25.9 ± 1.8 | 31.8 ± 2.1 | 24.4 ± 3.2 | 28.9 ± 1.2 | 27.2 ± 2.2 | 33.6 ± 1.4* | 29.0 ± 0.8 | 33.8 ± 1.2 |
Values are means ± SD, comparing starting point to end point, significant differences were at *p < 0.05 for the same treatment.